CSL confirms buyout interest in Vifor, and a deal could come soon: reportnews2021-12-13T14:34:19+00:00December 13th, 2021|Fierce Pharma|
Salix taps TikTok for the first time in constipation campaign pushnews2021-12-13T12:21:11+00:00December 13th, 2021|Fierce Pharma|
ASH: Novartis thinks it knows why Kymriah failed in earlier lymphoma but shifts focus to next-gen CAR-T medsnews2021-12-13T07:40:37+00:00December 13th, 2021|Fierce Pharma|
Sanofi, Regeneron plot Dupixent filing in young eczema patients, advancing drug’s megablockbuster ambitionsnews2021-12-10T19:56:30+00:00December 10th, 2021|Fierce Pharma|
Lawmakers blast pharma for ‘outrageous’ prices and ‘anticompetitive conduct’ in culmination of 3-year probenews2021-12-10T15:56:04+00:00December 10th, 2021|Fierce Pharma|
ASH: Sanofi, Johnson & Johnson on collision course with Sarclisa, Darzalex 4-drug regimens in myelomanews2021-12-10T15:33:45+00:00December 10th, 2021|Fierce Pharma|
Bayer targets 100% green packaging for consumer health brands by 2030 as part of €100 million sustainability plannews2021-12-10T15:18:36+00:00December 10th, 2021|Fierce Pharma|
GlaxoSmithKline vet departs for Vifor, the rumored target of a $7.1B CSL buyoutnews2021-12-10T14:31:05+00:00December 10th, 2021|Fierce Pharma|
Novartis CEO Narashimhan confirms interest in purchase of generics unit Sandoz: reportnews2021-12-10T14:05:03+00:00December 10th, 2021|Fierce Pharma|
Merck, Eisai’s 007 goes down as Keytruda-Lenvima combo fails in newly diagnosed lung cancernews2021-12-10T09:49:05+00:00December 10th, 2021|Fierce Pharma|
